Albemarle (NYSE:ALB) reported a sharply stronger start to 2026, with management citing higher lithium pricing, increased volumes and cost improvements across its energy storage and specialties businesses.
On the company’s first-quarter earnings call, Chief Executive Officer Kent Masters said Albema
Alta Equipment Group (NYSE:ALTG) reported lower first-quarter revenue and adjusted EBITDA as management said harsh winter weather and a pull-forward of equipment purchases into the prior quarter weighed on activity, while the company maintained that underlying demand trends remain healthy.
Chairman
American Homes 4 Rent (NYSE:AMH) said its first quarter of 2026 began with solid seasonal demand, record March leasing volumes and continued momentum into April, while management left its full-year outlook unchanged.
On the company’s May 7 earnings call, Chief Executive Officer Bryan Smith said the
Assured Guaranty (NYSE:AGO) reported a stronger start to 2026 in new business production, with management pointing to higher demand across U.S. public finance, non-U.S. public finance and global structured finance, while also signaling a near-term slowdown in share repurchases as it allocates capita
American Healthcare REIT (NYSE:AHR) raised its 2026 outlook after reporting another quarter of double-digit same-store net operating income growth, supported by strength in its Trilogy integrated senior health campus business and senior housing operating portfolio.
On the company’s first-quarter ea
Arbor Realty Trust (NYSE:ABR) executives said the company is making progress reducing troubled assets but warned that higher long-term rates are extending the timeline for resolutions and weighing on earnings.
On the company’s first-quarter 2026 earnings call, President and Chief Executive Officer
Ares Commercial Real Estate (NYSE:ACRE) reported a first-quarter loss as higher credit reserves tied to two large troubled loans weighed on results, while management said it continued to reshape the portfolio through new originations, asset resolutions and reduced office exposure.
Chief Executive O
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
